No fumes. Opta por una dieta saludable. Las vitaminas antioxidantes que hay en las frutas y los vegetales contribuyen a mantener la salud de los ojos. Los alimentos que no son de carne comprenden leche, queso, yogur, cereales de grano entero y pan de trigo integral.

Author:Nijin Molkree
Country:Cayman Islands
Language:English (Spanish)
Published (Last):22 January 2016
PDF File Size:14.64 Mb
ePub File Size:18.71 Mb
Price:Free* [*Free Regsitration Required]

False myths about early and intermediate AMD 1. From some time to this part, therapies of Photobiomodulation PBM of the retina have been developed with successful results. This treatment reduces macular drusen, improves visual acuity, contrast sensitivity and microperimetry as it has been published in different studies , where no complications have been reported in hundreds of treated cases and it has been considered safe and effective.

Ask Dr Orduna if Lumithera Valeda is a treatment option for you. The main photoacceptor of the treatment is cytochrome C oxidase, which is found in the cellular mitochondria. Although it is true that there is not enough scientific evidence to directly link the decline volume and number of macular drusens, after Photobiomodulation PBM with a slowdown in degenerative processes such as AMD, The international scientific community agrees on the importance and magnitude of this problem and the need to seek for solutions.

What part of the retina is damaged in AMD. The macula, which is the central part of vision. The disease is located in the external retina, at the level of the retinal pigment epithelium RPE and the Bruch membrane of the choriocapillary.

RPE fulfils several crucial functions in the retina: the external retinal barrier, protection of the retina against oxidative stress, supply of nutrients to the neurosensorial retina, elimination of waste products, phagocytosis of the external segments of the photoreceptors, synthesis and release of growth factors, etc. Age-related macular degeneration AMD is the leading cause of visual impairment in developed countries. It affects multiple activities of daily life such as reading, computer use, mobile phone use, driving, and in advanced cases produces a significant decline in visual quality.

Currently, despite the complexity of AMD, we know that it is related to inflammation and oxidative stress. Is that true? Not in the case of red and infrared radiation. Visible radiation is made up of different electromagnetic waves of a certain magnitude. The biological effect of the treatment is produced by near-infrared radiation nm.

Photobiomodulation PBM consists of non-invasive irradiation of tissue with radiation in the near-infrared spectrum, specifically with wavelengths of nm, nm and nm that is directed at the mitochondria of the cells of the retina to control oxidative stress and reduce inflammation. Therefore those people suffering from early and intermediate stages of Age-related Macular Degeneration can benefit from Photobiomodulation PBM treatment by improving their visual acuity and contrast sensitivity and by decreasing the size of drusen as demonstrated in the TORPA I clinical study where the therapeutic effect of Macular Photobiomodulation PBM included the neutralization of ROS reactive oxygen species , promoting cell survival and inhibiting the inflammatory response.

It acts at the level of the cellular mitochondria to improve metabolism, control oxidative stress and decrease inflammation. The mitochondria are the cellular organelles where energy is synthesized, which can be stimulated depending on the composition and intensity of the incident radiation. The patient will be able to lead a normal life at all times, both before and after each session.

The annual treatment consists of two cycles of three weekly sessions for three weeks in a row, 4 minutes each day per eye. Both cycles are separated by 6 months. One month after the end of the first cycle, a complete visual function check is performed. In the most os cases, positive results are reached from the first session. Retreatment needed at 6 month interval approx.

Improvements in visual acuity, contrast sensitivity, microperimetry, and drusen volume reduction have been found as demonstrated in the Lighsite I and Torpa I and II studies. The patient will be able to lead a normal life at all times, both before and after treatment.

Treatment with red and near-infrared radiation has been studied to improve the capacity of mitochondria and reduce the harmful effects of other agents. Each session lasts less than 5 minutes per eye. After analyzing the results of the exam, Dr Orduna and his team will offer you the most appropriate treatment. If the patient meets the inclusion criteria for treatment by macular PBM with Lumithera Valeda, the sessions of the first treatment cycle will be scheduled for three consecutive weeks.

Day 2: The treatment The annual treatment is applied in two cycles with a 6 month interval. The first cycle consists of 9 consecutive sessions: 3 days in a row, three consecutive weeks, 4 minutes per eye.

One month after the first cycle of photobiomodulation you will have a follow up appointment with Dr Orduna; six months later you will go for a check-up and the second cycle of macular biophotomodulation MBP treatment.

No side effects have been reported in any study. Day 3: The follow-up After one month a monitoring review will be carried out to evaluate the effects of the first biophotomodulation cycle and to study the evolution of the case. In this review we will perform macular OCT, angio-oCT, visual acuity, contrast sensitivity, microperimetry, and imaging tests retinography and autofluorescence.

After six months, the patient will go for another check-up and the second cycle of treatment. In the same way, the second cycle consists of 9 consecutive treatment sessions, 3 days in a row, three consecutive weeks, 4 minutes per eye, with the consequent complete revision.

His innovative approach treating eye diseases with laser technology has been recognised by the international medical community. Dr Orduna responds Who is a candidate for treatment with Valeda? Who is NOT suitable for treatment with Valeda? Patients who have known reactions to photoexposure or who have central nervous system diseases activated by radiation, e. Patients should not receive Valeda treatment within 30 days of being treated with a photosensitizing drug without first consulting with Dr Orduna.

What does treatment with Valeda involve? If you wear glasses or contact lenses, they will be removed before starting treatment. It is not necessary to dilate your pupils to receive treatment. You will remain comfortably seated in front of the Valeda Light Delivery System. The treatment of both eyes will take less than 10 minutes, 5 minutes per eye.

Clinical trials have indicated benefits in visual function visual acuity, contrast sensitivity, and microperimetry after a treatment administered 3 times a week for 3 weeks. What are the clinical benefits of treatment with Valeda? Treatment with Valeda improves overall visual function, including visual acuity, contrast sensitivity and microperimetry. Subsequent retinograms and OCTs also show improvement and decrease in drusen volume.

What are the possible side effects of treatment with Valeda? Photobiomodulation PBM is a treatment based on the application of radiation at three wavelengths, nm, nm and nm that stimulates metabolic activity and inhibits inflammation and cell death.

PBM has been used in various diseases for decades with a positive safety profile. In clinical trials on patients with dry AMD and Valeda, photobiomodulator treatment has been shown to be safe and without side effects. What can I expect during and after treatment with Valeda?

Can the treatment be done even if there are cataracts? Los pacientes pueden recibir el tratamiento con Valeda aunque padezcan cataratas. Latest news Check out the latest news about macular drusen and AMD, as well as the innovative treatments we administer in our eye clinic.


Macular Photobiomodulation (PBM)



¿Qué son las drusas maculares?


Related Articles